Where to invest $50,000 in ASX shares

Analysts think these shares could be great destinations for your hard-earned money.

| More on:
A happy young couple lie on a wooden deck using a skateboard for a pillow.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you are lucky enough to be sitting on $50,000 and wondering how to put it to work in the share market, then read on.

With interest rates falling and long-term growth back in focus, now could be a great time to build a high-quality ASX share portfolio aimed at capital appreciation.

But rather than chasing short-term trades or speculative names, investors may want to consider businesses with proven track records, strong global expansion, and resilient earnings.

With that in mind, here are five standout ASX shares that analysts think could form the foundation of a smart, long-term portfolio. They are as follows:

Cochlear Ltd (ASX: COH)

Cochlear is a global leader in hearing implants technology. With an ageing global population and rising rates of hearing loss, demand for Cochlear's products is only expected to increase over the next decade. The company also invests heavily in R&D, which keeps it ahead of the pack with next-generation devices.

Last week, UBS upgraded its shares to a buy rating with a $325.00 price target.

REA Group Ltd (ASX: REA)

Another ASX share to look at with the $50,000 is REA Group. It is the name behind realestate.com.au, which dominates the online property advertising space in Australia. While the housing market moves in cycles, REA Group has built an incredibly sticky platform with pricing power and deep competitive moats.

Bell Potter is bullish on REA Group and has a buy rating and $267.00 price target on its shares.

ResMed Inc. (ASX: RMD)

ResMed is a major player in the treatment of obstructive sleep apnoea and other sleep and breathing disorders. While concerns around weight-loss drugs spooked the market last year, ResMed has continued to post strong results, including robust mask sales, margin expansion, and double-digit earnings growth. It also benefits from an ageing population and increasing awareness of sleep health.

Macquarie has an outperform rating and $48.00 price target on this ASX share.

WiseTech Global Ltd (ASX: WTC)

WiseTech could be an ASX share to buy with the $50,000. It is a global logistics software provider, best known for its CargoWise platform. It serves some of the world's largest freight forwarders and is capitalising on the structural shift toward digital supply chain management. Recurring revenue, global customer wins, and ongoing product innovation give WiseTech a long runway for growth.

The team at Macquarie has an outperform rating and $152.70 price target on its shares.

Xero Ltd (ASX: XRO)

Finally, Xero could be worth considering. It offers cloud-based accounting software to small and medium-sized businesses. It is one of the most recognisable tech names in the region, with a sticky, subscription-based model and strong international growth potential. And with 4.4 million subscribers on its platform and an estimated 100 million total addressable market, it still has a very long growth runway.

Morgan Stanley has an overweight rating and $220.00 price target on its shares.

Motley Fool contributor James Mickleboro has positions in Cochlear, REA Group, ResMed, WiseTech Global, and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear, Macquarie Group, ResMed, WiseTech Global, and Xero. The Motley Fool Australia has positions in and has recommended Macquarie Group, ResMed, WiseTech Global, and Xero. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

woman looking at iPhone whilst working on a laptop
Growth Shares

3 of the best Australian shares to buy and hold until 2035

It could be worth holding tightly to these shares for the long term.

Read more »

Two large bulls fight against each other in the dust.
Growth Shares

2 quality ASX 200 stocks to buy for your 2026 portfolio

Brokers are bullish on these mainstay sector picks.

Read more »

A woman stands at her desk looking a her phone with a panoramic view of the harbour bridge in the windows behind her with work colleagues in the background.
Growth Shares

Analysts say these ASX 200 shares could rise 30% to 40%

Big returns could be on offer with these growing stocks.

Read more »

Four piles of coins, each getting higher, with trees on them.
Growth Shares

2 ASX 200 shares that could be top buys for growth

These two businesses have an exciting future.

Read more »

Man pointing at a blue rising share price graph.
Growth Shares

The 3 biggest ASX multibaggers in 2025

These billion-dollar ASX companies have delivered eye-catching multibagger returns in 2025.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Growth Shares

These world class ASX 200 growth shares could rise 40% to 80%

These high-quality shares are seriously undervalued according to brokers.

Read more »

A male ASX investor sits cross-legged with a laptop computer in his lap with a slightly crazed, happy, excited look on his face while next to him a graphic of a rocket shoots upwards with graphics of stars scattered around it
Healthcare Shares

Up 10x since July, could this hot ASX stock be the next Droneshield?

Investors chase asymmetric upside and 4DMedical is one of the ASX's hottest stocks right now.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Growth Shares

3 ASX mid-cap rockets that could become future blue chips

These stocks could be destined for big things in the future according to analysts.

Read more »